Literature DB >> 12527620

Nuclear accumulation of p53 is a potential marker for the development of squamous cell lung cancer in smokers.

Chandrika J Piyathilake1, Andra R Frost, Upender Manne, Heidi Weiss, Douglas C Heimburger, William E Grizzle.   

Abstract

STUDY
OBJECTIVES: To determine whether the nuclear accumulation of p53 in patients with early bronchial neoplasia represents an altered susceptibility for the development of lung cancer. PATIENTS AND MEASUREMENTS: We evaluated the percentage of cells accumulating nuclear p53 immunohistochemically in squamous cell carcinoma (SCC) of the lung, the associated uninvolved bronchial mucosa, and epithelial hyperplasia in 60 archival lung specimens of smokers and in the normal bronchial epithelium and hyperplastic lesions of 60 smokers who had not developed lung cancer.
RESULTS: The percentage of cells accumulating p53 was significantly higher in SCC-associated uninvolved bronchial epithelia of (mean [+/- SD], 4 +/- 0.9%) and in specimens from patients with epithelial hyperplasia (mean, 9 +/- 2%) compared to the percentage of cells from the bronchial epithelia of (mean, 0.5 +/- 0.2%) and in specimens from patients with epithelial hyperplasia (mean, 1.5 +/- 0.5%) who were smokers who had not developed lung cancer (p = 0.0002 and p = 0.0004, respectively). We also observed a statistically significant stepwise increase in the percentage of cells accumulating p53 from SCC-associated uninvolved bronchial epithelium to those from a patient with epithelial hyperplasia to those from a patient with SCC (mean, 35 +/- 4%), suggesting the involvement of p53 accumulation in the development of SCC (p <or= 0.05 for all comparisons). The accumulation of p53 in SCC cells was not significantly associated with the size of the tumor, nodal involvement, the stage of the disease, the presence or absence of metastasis, the grade of differentiation, or survival of the disease, indicating its lack of association with the clinical progression of the disease.
CONCLUSIONS: These results suggested that p53 accumulation is an early event in lung carcinogenesis and potentially could be useful in the identification of smokers who are at risk of developing SCC, but not in the estimation of survival of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527620     DOI: 10.1378/chest.123.1.181

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  5 in total

1.  Standards for immunohistochemical imaging: a protein reference device for biomarker quantitation.

Authors:  Donald H Atha; Upender Manne; William E Grizzle; Paul D Wagner; Sudhir Srivastava; Vytas Reipa
Journal:  J Histochem Cytochem       Date:  2010-08-30       Impact factor: 2.479

2.  RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status.

Authors:  Mohd Feroz Mohd Omar; Kosei Ito; Min En Nga; Ross Soo; Bee Keow Peh; Tuty Muliana Ismail; Bhavin Thakkar; Richie Soong; Yoshiaki Ito; Manuel Salto-Tellez
Journal:  Pathol Oncol Res       Date:  2012-06-24       Impact factor: 3.201

3.  Dietary diindolylmethane suppresses inflammation-driven lung squamous cell carcinoma in mice.

Authors:  Jung Min Song; Xuemin Qian; Fitsum Teferi; Jing Pan; Yian Wang; Fekadu Kassie
Journal:  Cancer Prev Res (Phila)       Date:  2014-11-17

4.  EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study.

Authors:  Vítor Sousa; Joana Espírito Santo; Maria Silva; Teresa Cabral; Ana Maria Alarcão; Ana Gomes; Patrícia Couceiro; Lina Carvalho
Journal:  Virchows Arch       Date:  2011-03-22       Impact factor: 4.064

Review 5.  Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer.

Authors:  Alphy Rose-James; Sreelekha Tt
Journal:  Lung Cancer Int       Date:  2012-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.